KNSA · Kiniksa Pharmaceuticals Interna
$76.27
-0.28% last session
End-of-day data · close of 2026-09-11
Market cap
$6B
Enterprise value
$5B
Trailing P/E
79.7
Forward P/E
47.3
Dividend yield
—
Beta
0.09
Avg volume
1M
Employees
0K
Daily Change %
-0.28%
5 Days Change
0.78%
10 Days Change
-0.14%
30 Days Change
0.93%
60 Days Change
23.77%
Month to Day Change
-0.96%
Year to Day Change
90.35%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — KNSA
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-07-30
Latest call per bank · past 12 months
Goldman Sachs
Buy$90.00
+17.7% vs priceJP Morgan
Overweight$107
+39.9% vs priceCitigroup
Buy$100
+30.8% vs priceWells Fargo
Overweight$74.00
-3.2% vs priceJefferies
Buy$71.00
-7.2% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-30 | Goldman Sachs | Maintains | Buy | $75.00 → $90.00 |
| 2026-07-29 | JP Morgan | Maintains | Overweight | $72.00 → $107 |
| 2026-07-29 | Canaccord Genuity | Maintains | Buy | $64.00 → $98.00 |
| 2026-07-29 | Wedbush | Maintains | Outperform | $72.00 → $99.00 |
| 2026-07-29 | Citigroup | Maintains | Buy | $60.00 → $100 |
| 2026-07-23 | Goldman Sachs | Maintains | Buy | $60.00 → $75.00 |
| 2026-07-13 | Wells Fargo | Maintains | Overweight | $57.00 → $74.00 |
| 2026-06-29 | Wedbush | Maintains | Outperform | $59.00 → $72.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-09-11
- RSI (14): RSI is 49 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 4.4% above the 50-day MA ($73.07).
- Price vs 200-day MA: Trading 42.3% above the 200-day MA ($53.59).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-0.84) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($35.42) and high ($80.92).
KNSA Price Chart
Loading chart for KNSA…
Fundamentals
About Kiniksa Pharmaceuticals Interna
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
More in Drug Manufacturers - Specialty & Generic
TAK
Takeda Pharmaceutical Company L
$58B 16.8% YTD
TEVA
Teva Pharmaceutical Industries
$42B 18.1% YTD
HLN
Haleon plc
$41B -6.9% YTD
ZTS
Zoetis Inc.
$30B -40.8% YTD
UTHR
United Therapeutics Corporation
$22B 4.0% YTD
VTRS
Viatris Inc.
$19B 35.6% YTD
NBIX
Neurocrine Biosciences, Inc.
$16B 9.4% YTD
ELAN
Elanco Animal Health Incorporat
$11B 4.1% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.